Almari Conradie
1 ta ish
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt +16
Maqola20152 iqtibosABI